Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE LAMIVUDINE.
EMTRICITABINE vs STAVUDINE; LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate thymidine triphosphate and causing chain termination after incorporation. Lamivudine is also an NRTI that inhibits HIV-1 reverse transcriptase via similar competition and chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
Stavudine 30 mg plus lamivudine 150 mg orally twice daily. For weight <60 kg: stavudine 30 mg twice daily; for weight ≥60 kg: stavudine 40 mg twice daily (but fixed-dose combination typically uses 30 mg).
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Stavudine: 1.5-2 h (adults) but intracellular active triphosphate t1/2 3.5-6 h; Lamivudine: 5-7 h (adults) with intracellular triphosphate t1/2 10.5-15.5 h. Renal impairment prolongs elimination; dose adjustment needed for CrCl <50 mL/min.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Stavudine: 40% renal (unchanged) via glomerular filtration and tubular secretion. Lamivudine: 70% renal (unchanged) via glomerular filtration and tubular secretion. Both: minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."